List of Excipients in Branded Drug PROGESTERONE VAGINAL INSERT

Generic Drugs Containing PROGESTERONE VAGINAL INSERT

Company	Ingredient	NDC	Excipient
XIROMED LLC	progesterone	70700-201	ADIPIC ACID
XIROMED LLC	progesterone	70700-201	LACTOSE MONOHYDRATE
XIROMED LLC	progesterone	70700-201	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in PROGESTERONE VAGINAL INSERT?

# Of NDCs	Excipient
1	ADIPIC ACID
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE

Progesterone Vaginal Insert Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Progesterone vaginal inserts have commercial potential in assisted reproductive technology, luteal-phase support, hormone replacement, and potentially contraceptive or fertility applications. The leading U.S. reference product is Endometrin, a 100 mg progesterone vaginal insert marketed by Ferring Pharmaceuticals. Its core formulation uses a compressed, rapidly disintegrating insert rather than a conventional cream, gel, or oil-based suppository. The strongest commercial opportunities are improved vaginal retention, reduced leakage, lower irritation, better manufacturing efficiency, differentiated dosing, and alternative delivery systems.

What is the FDA status of progesterone vaginal inserts?

Endometrin is FDA-approved for progesterone supplementation or replacement as part of an assisted reproductive technology treatment program in infertile women. The product contains 100 mg micronized progesterone in a vaginal insert dosage form. The FDA approved Endometrin in 2007 under NDA 021503.[1]

Product	Active ingredient	Strength	Dosage form	U.S. sponsor	Primary FDA use
Endometrin	Progesterone	100 mg	Vaginal insert	Ferring Pharmaceuticals	Luteal support in ART
Crinone	Progesterone	4% and 8%	Vaginal gel	Various rights holders	Luteal support and secondary amenorrhea
Prochieve	Progesterone	4% and 8%	Vaginal gel	Previously Columbia Laboratories	Progesterone supplementation
Vaginal progesterone capsules	Progesterone	Various	Soft or hard capsule	Multiple manufacturers	Uses vary by jurisdiction

Endometrin is distinct from vaginal progesterone gels and suppositories because it is a solid insert designed for placement with an applicator. The format supports unit-dose packaging, controlled manufacturing, and a relatively low excipient burden.

The approved label identifies lactose monohydrate, polyvinylpyrrolidone, polysorbate 80, colloidal silicon dioxide, and sodium lauryl sulfate as inactive ingredients.[1] Any reformulation must preserve progesterone content uniformity, disintegration, vaginal compatibility, chemical stability, microbiological quality, and clinical performance.

What excipients are used in the Endometrin progesterone vaginal insert?

The Endometrin excipient system performs several functions:

Excipient	Likely formulation role	Commercial relevance
Lactose monohydrate	Diluent and water-soluble bulking agent	Supports tablet mass, compressibility, and rapid dissolution
Polyvinylpyrrolidone	Binder	Improves mechanical strength during compression
Polysorbate 80	Wetting or dispersing agent	Supports wetting of hydrophobic micronized progesterone
Colloidal silicon dioxide	Glidant and flow aid	Improves powder flow and content uniformity
Sodium lauryl sulfate	Surfactant and wetting agent	Can improve dissolution but requires vaginal tolerability control

Progesterone has low aqueous solubility. Micronization improves surface area, but the active remains sensitive to formulation and process conditions. Surfactant selection, particle-size distribution, granulation, compression force, and disintegration behavior can materially affect drug release and local exposure.

The existing excipient platform is commercially conservative. A competing product does not need to reproduce the same composition. It needs to demonstrate equivalent pharmaceutical quality and, where required, bioequivalence or therapeutic equivalence under the applicable FDA pathway.

How should excipients be selected for progesterone vaginal inserts?

Excipient selection should start with the product’s target performance rather than with a simple substitution of the reference formulation. The main design variables are vaginal residence time, release rate, comfort, leakage, dose uniformity, manufacturing robustness, and storage stability.

1. Water-soluble fillers

Lactose, mannitol, sorbitol, and selected grades of microcrystalline cellulose can provide bulk and compression characteristics.

Lactose supports rapid dissolution and is familiar to regulators. Its limitations include potential incompatibility with certain primary amine-containing materials and sensitivity to grade-specific flow and moisture properties. Mannitol can improve mouthfeel in oral products, but that advantage has little relevance vaginally. It may provide a lower-hygroscopicity alternative to lactose.

Microcrystalline cellulose can improve tablet strength but may slow disintegration or leave a more persistent residue. It is more suitable where mechanical integrity is a priority than where rapid breakup is the primary objective.

2. Binders

Polyvinylpyrrolidone is a conventional binder for direct compression or granulation. Alternative binders include hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, and selected grades of polyethylene glycol.

Higher binder levels can reduce friability but may prolong disintegration. A vaginal insert requires a narrow balance. The unit must survive packaging, transport, and applicator insertion without excessive dusting, yet break down rapidly enough to release progesterone at the intended site.

3. Wetting agents and surfactants

Progesterone is hydrophobic, so wetting agents are central to dissolution performance. Polysorbate 80 and sodium lauryl sulfate are effective but require vaginal irritation testing and extractables or impurity assessment.

Commercial alternatives include poloxamers, poloxamer 188, poloxamer 407, lecithin derivatives, and selected nonionic surfactants. Poloxamers can provide both wetting and thermoresponsive behavior, but they may alter insert hardness and residual moisture. Surfactant concentration should be minimized to the level required for reproducible release.

4. Mucoadhesive polymers

Mucoadhesive polymers are the principal route to product differentiation. Candidate materials include carbomers, polycarbophil, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, hyaluronic acid, and selected thiolated polymers.

Mucoadhesion can reduce leakage and increase local residence time. It can also create risks:

• Excessive adhesion may cause discomfort or difficult removal.
• Swelling can increase residue and alter patient acceptability.
• Polymer acidity may cause irritation or affect vaginal pH.
• Polymer hydration can change progesterone release over time.
• Batch-to-batch polymer variability can affect performance.

A mucoadhesive insert should not be assumed to improve clinical outcomes merely because it remains in place longer. Exposure at the target tissue, systemic progesterone levels, patient comfort, and pregnancy-related outcomes must be assessed.

5. Lipid and self-emulsifying systems

Lipid excipients can improve progesterone solubilization. Potential materials include medium-chain triglycerides, glyceryl esters, polyethylene glycol esters, and self-emulsifying drug delivery systems.

These systems may increase dissolution but can also increase leakage, soften the dosage form, complicate compression, and create packaging or stability challenges. Lipid-based inserts are more naturally suited to molded pessaries, ovules, or soft inserts than to conventional compressed tablets.

What formulations are commercially protected or differentiated?

The main formulation opportunities are listed below.

Formulation concept	Primary benefit	Main risk	IP potential
Rapid-disintegrating compressed insert	Simple manufacturing and low residue	Leakage and short residence time	Composition and process claims
Mucoadhesive insert	Longer vaginal retention	Irritation and residue	Polymer ratio, adhesion profile, use claims
Controlled-release insert	Less frequent dosing	Dose dumping or inadequate exposure	Release matrix and treatment regimen claims
Effervescent insert	Rapid dispersion	Local irritation and gas generation	Composition and disintegration claims
Bioadhesive hydrogel insert	High tissue contact	Manufacturing complexity	Polymer network and delivery claims
Lipid-based insert	Improved progesterone solubilization	Softening and leakage	Vehicle composition and process claims
Vaginal ring or implant	Extended dosing	Device complexity	Drug-device combination claims
Applicator-integrated insert	Better placement and hygiene	Packaging and device costs	Applicator and insertion-system claims

A lower-cost generic strategy would normally favor a formulation that remains close to the reference product in dosage form, strength, release behavior, and excipient function. A branded lifecycle strategy would favor a differentiated platform that addresses patient complaints associated with leakage, messiness, insertion difficulty, or twice-daily dosing.

How strong is the patent estate for progesterone vaginal inserts?

Patent strength depends on the specific product, jurisdiction, listed patents, and claim scope. The most valuable claim categories are:

1. Composition claims covering progesterone particle size, excipient ratios, and insert structure.
2. Dosage-form claims covering compressed vaginal inserts or multi-layer inserts.
3. Method-of-use claims covering luteal support, implantation support, or pregnancy maintenance.
4. Manufacturing claims covering blending, granulation, compression, coating, and packaging.
5. Applicator and drug-device claims.
6. Stability claims covering moisture-controlled packaging and shelf life.

The original Endometrin product has been marketed for more than a decade, so basic composition claims may face expiration or validity pressure depending on the specific patent family. A current Orange Book review is required to identify live U.S. patents, pediatric extensions, and any listed method-of-use patents.[2] Patent term generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment and any patent-term extension.[3]

The strongest new patent position would likely come from a formulation that creates a measurable technical distinction, such as:

• A defined progesterone particle-size distribution.
• A polymer-surfactant system that reduces leakage while maintaining rapid release.
• A controlled-release insert that supports once-daily administration.
• A low-irritation surfactant system.
• A moisture-resistant packaging and manufacturing process.
• A novel applicator that improves placement or reduces contamination.

A patent that only substitutes one conventional excipient for another may face obviousness challenges unless it demonstrates an unexpected dissolution, retention, stability, tolerability, or clinical result.

When does progesterone vaginal insert exclusivity expire?

FDA regulatory exclusivity and patent exclusivity must be analyzed separately.

Endometrin received approval in 2007. New chemical entity exclusivity was not available because progesterone had long been established as an active pharmaceutical ingredient. The principal commercial barriers therefore involve patents, product-specific regulatory requirements, manufacturing know-how, and clinical or bioequivalence expectations rather than NCE exclusivity.[1,4]

Exclusivity category	Relevance to progesterone vaginal inserts
New chemical entity exclusivity	Generally unavailable for established progesterone
New clinical investigation exclusivity	Possible only for qualifying new clinical data
Orphan exclusivity	Not generally applicable to standard ART luteal support
Pediatric exclusivity	Possible only if awarded for a qualifying program
Patent-term extension	Product- and patent-specific
Listed method-of-use patents	May affect Paragraph IV litigation
Trade secrets	Manufacturing and analytical methods may remain relevant after patent expiry

A generic applicant could pursue an ANDA if the reference product and regulatory pathway support that approach. A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. The filing could trigger patent litigation under the Hatch-Waxman framework and potentially impose a 30-month stay, subject to statutory exceptions and court events.[5]

What FDA regulatory pathway applies to a generic progesterone vaginal insert?

A generic applicant would generally evaluate an ANDA referencing Endometrin, provided FDA identifies the product as therapeutically equivalent and the dosage form can meet applicable requirements. Key development work would include:

• Assay and content uniformity.
• Impurity and degradation profiling.
• Disintegration and dissolution.
• Progesterone particle-size characterization.
• Microbiological quality.
• Stability under controlled and accelerated conditions.
• Applicator compatibility.
• Comparative bioavailability or bioequivalence.
• Local tolerability where required.
• Extractables and leachables for packaging or applicator systems.

Vaginal products can present challenges not captured by conventional oral solid-dose testing. In vitro release may not predict vaginal exposure. A mucoadhesive or controlled-release formulation may require a more extensive clinical package than a close formulation with similar release behavior.

Inactive ingredients also require scrutiny. An excipient may be acceptable for oral use but have limited precedent for chronic vaginal administration. Concentration, exposure duration, pH, osmolality, irritation, and effects on vaginal flora should be evaluated.

Which companies are challenging the progesterone vaginal insert market?

The competitive field includes originators, generic pharmaceutical companies, specialty fertility companies, and drug-delivery developers. Competition is not limited to identical inserts.

Competitor category	Examples of products or capabilities	Competitive threat
Reference-product sponsor	Ferring and Endometrin	Brand recognition and physician familiarity
Vaginal gel manufacturers	Crinone and related products	Established clinical use and flexible dosing
Generic manufacturers	Potential ANDA applicants	Price erosion and pharmacy substitution
Compounded pharmacies	Customized progesterone suppositories	Low price and formulation flexibility
Fertility specialists	Protocol-specific progesterone products	Prescriber and clinic influence
Drug-delivery developers	Rings, gels, implants, and bioadhesive systems	Lower dosing frequency and improved retention

Compounded progesterone products may compete on cost but do not provide the same FDA-approved commercial pathway, quality controls, or substitution status as an approved generic. Their use can be influenced by availability, clinician preference, local pharmacy relationships, and payer policies.

What commercial opportunities exist for progesterone vaginal inserts?

Generic substitution

The clearest opportunity is a lower-cost product with equivalent strength and dosage form. Value depends on:

• The number of approved or pending ANDAs.
• Pharmacy benefit substitution.
• Payer preference.
• Manufacturing cost per insert.
• Applicator and packaging costs.
• Litigation timing.
• Reference-product pricing.

A generic insert can achieve a cost advantage through direct compression, high-throughput blister packaging, and simplified applicator design. The formulation should avoid unnecessary excipients that create patent, tolerability, or supply-chain risks.

Once-daily dosing

A once-daily insert would have strong commercial value if it produces reliable progesterone exposure and acceptable vaginal retention. It could improve adherence relative to twice-daily use. The product would likely require new clinical or comparative pharmacokinetic evidence and may face method-of-use and formulation patent scrutiny.

Reduced leakage

Leakage and residue are practical disadvantages of vaginal progesterone products. A low-residue insert that maintains tissue exposure could support premium positioning. The most defensible claims would link a defined excipient architecture to measurable retention, reduced discharge, or improved patient-reported acceptability.

Fertility-clinic contracting

Fertility clinics can influence product selection through protocol standardization and purchasing agreements. Commercial advantages may arise from:

• Unit-dose packaging.
• Simplified inventory management.
• Reliable supply.
• Applicators designed for clinic or home use.
• Patient-support programs.
• Contract pricing for high-volume clinics.

Geographic expansion

Regulatory requirements vary by market. The United States emphasizes FDA approval and Orange Book substitution. The European Union evaluates medicinal-product quality, safety, efficacy, and national reimbursement conditions. Emerging markets may provide opportunities for locally manufactured products but can present higher risks involving quality enforcement, trademark protection, and patent assessment.

What manufacturing and intellectual-property barriers exist?

The most important manufacturing barriers are progesterone content uniformity, powder flow, compression reproducibility, moisture control, and prevention of insert breakage. Micronized progesterone can segregate from excipients if particle size, density, or blending time is poorly controlled.

Process-development priorities include:

• Controlled particle-size distribution.
• Low-shear blending that limits segregation.
• Compression-force optimization.
• In-process weight and hardness control.
• Moisture-protective packaging.
• Applicator insertion-force testing.
• Defined disintegration and dissolution specifications.
• Validated cleaning procedures for hormone-containing equipment.

Trade secrets may provide meaningful protection even where composition patents are weak. These can include blending order, granulation endpoint, compression parameters, environmental controls, analytical methods, and packaging operations.

How does Endometrin compare with vaginal progesterone gels?

Attribute	Progesterone vaginal insert	Vaginal gel
Dosing format	Solid unit dose	Semi-solid applicator dose
Excipients	Usually compact excipient system	Gel-forming and aqueous or emulsion system
Leakage	May produce residue or discharge	Often associated with gel discharge
Manufacturing	Compression or molding	Homogenization and fill-finish
Differentiation	Adhesion, release, applicator	Gel retention, dosing, polymer system
Generic complexity	Solid-dose and vaginal performance issues	Semisolid equivalence and device issues
Patient preference	Cleaner handling may be possible	Familiar but potentially messy

The insert format offers a stronger path toward low-cost manufacturing and unit-dose packaging. The gel format can offer easier spreading and tissue coverage but often faces greater patient complaints concerning discharge and messiness.

What patent litigation and settlement risks affect generic entry?

A Paragraph IV filing against a listed patent can produce litigation before commercial launch. The principal risks include:

• A 30-month stay of FDA approval.
• Preliminary injunction requests.
• Settlement restrictions on launch timing.
• Authorized-generic competition.
• At-risk launch damages.
• Invalidity or noninfringement findings.
• Patent listing disputes.
• Regulatory exclusivity for a first Paragraph IV filer.

Settlement agreements should be reviewed for launch dates, supply terms, license rights, authorized-generic provisions, acceleration clauses, and restrictions on formulation changes. A formulation patent may be more difficult to design around than a narrow method-of-use patent if the product must retain the same dosage form and release profile.

Key Takeaways

• Endometrin is the principal U.S. reference product for progesterone vaginal inserts and was approved in 2007.
• The labeled excipient system includes lactose monohydrate, polyvinylpyrrolidone, polysorbate 80, colloidal silicon dioxide, and sodium lauryl sulfate.
• The strongest formulation opportunities involve retention, leakage reduction, low irritation, controlled release, and once-daily dosing.
• Generic development should prioritize a close reference formulation, low manufacturing cost, reliable disintegration, and a clear Orange Book and Paragraph IV strategy.
• New branded products need measurable technical differentiation rather than simple excipient substitution.
• Mucoadhesive polymers, poloxamers, lipid vehicles, and improved applicators offer the main platform opportunities.
• The primary commercial competitors are vaginal gels, compounded suppositories, generic inserts, and extended-release delivery systems.
• Manufacturing know-how can remain valuable even after basic composition patents expire.

FAQs

Is micronized progesterone required in a vaginal insert?

Micronization is not necessarily mandated by the dosage form, but it is highly relevant because progesterone has low aqueous solubility. Smaller particles can improve wetting and dissolution when the formulation and process maintain uniform distribution.

Can a progesterone vaginal insert use a new excipient?

A new or less-established vaginal excipient may require additional safety, tolerability, and regulatory justification. Prior approval in another route does not automatically establish suitability for vaginal administration.

Is a progesterone vaginal insert eligible for automatic pharmacy substitution?

Substitution depends on FDA therapeutic-equivalence determinations, reference-product status, state pharmacy law, and payer policy. Dosage-form similarity alone does not guarantee an AB rating.

What is the best commercial improvement over Endometrin?

The most commercially defensible improvements are reduced leakage, improved comfort, once-daily dosing, lower manufacturing cost, or a simpler applicator. Each claim requires supporting pharmaceutical and clinical evidence.

Can a company patent a new progesterone vaginal insert after the original product’s patents expire?

Yes. A later product may obtain patents on a novel formulation, release profile, excipient combination, manufacturing process, applicator, packaging system, or treatment regimen. The patent must satisfy novelty, nonobviousness, enablement, and written-description requirements.

References

1. U.S. Food and Drug Administration. (2007). Endometrin (progesterone) vaginal insert: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension.
4. U.S. Food and Drug Administration. (2019). Regulatory exclusivity.
5. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman Amendments and abbreviated new drug applications.